IN2012DN03042A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03042A
IN2012DN03042A IN3042DEN2012A IN2012DN03042A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A IN 3042DEN2012 A IN3042DEN2012 A IN 3042DEN2012A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A
Authority
IN
India
Prior art keywords
neuropeptide
obesity
diabetes
substituents
fragments
Prior art date
Application number
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03042A publication Critical patent/IN2012DN03042A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN3042DEN2012 2009-10-13 2010-10-08 IN2012DN03042A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
PCT/EP2010/065060 WO2011045232A2 (en) 2009-10-13 2010-10-08 Neuropeptide-2 receptor (y-2r) agonists

Publications (1)

Publication Number Publication Date
IN2012DN03042A true IN2012DN03042A (cs) 2015-07-31

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3042DEN2012 IN2012DN03042A (cs) 2009-10-13 2010-10-08

Country Status (7)

Country Link
US (1) US20110172147A1 (cs)
EP (1) EP2488195A2 (cs)
JP (1) JP2013507414A (cs)
CN (1) CN102596228A (cs)
CA (1) CA2776302A1 (cs)
IN (1) IN2012DN03042A (cs)
WO (1) WO2011045232A2 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
MX369259B (es) 2013-05-02 2019-11-04 Novo Nordisk As Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
BR112016010383A2 (pt) 2013-11-15 2017-12-05 Novo Nordisk As compostos de pyy seletivos e usos dos mesmos
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MY187047A (en) 2015-06-12 2021-08-27 Novo Nordisk As Selective pyy compounds and uses thereof
HUE063787T2 (hu) 2018-02-02 2024-01-28 Novo Nordisk As Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途
CN120092752A (zh) * 2025-05-09 2025-06-06 北京大学人民医院 三叉神经痛动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (cs) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
WO2006049681A2 (en) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
ES2381497T3 (es) * 2005-12-07 2012-05-28 F. Hoffmann-La Roche Ag Agonistas del receptor del neuropéptido-2
NZ602353A (en) * 2007-09-11 2014-06-27 Kode Biotech Ltd Peptide-lipid constructs and their use in diagnostic and therapeutic applications
CN102202681A (zh) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途

Also Published As

Publication number Publication date
US20110172147A1 (en) 2011-07-14
JP2013507414A (ja) 2013-03-04
WO2011045232A3 (en) 2011-06-16
CN102596228A (zh) 2012-07-18
EP2488195A2 (en) 2012-08-22
CA2776302A1 (en) 2011-04-21
WO2011045232A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
IN2012DN03042A (cs)
TW200806311A (en) Neuropeptide-2 receptor-agonists
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
GB0812642D0 (en) Compounds
MX2011012122A (es) Derivados de tiofeno.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IN2012DN03182A (cs)
PH12013500473A1 (en) Triazine-oxadiazoles
IN2012DN02139A (cs)
MX2012000704A (es) Agonistas de gpr119.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes